FDA approves drug to treat Duchenne muscular dystrophy

"U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx> · Thu, 09 Feb 2017 14:40:19 -0600

Title:     FDA approves drug to treat Duchenne muscular dystrophy

View as webpage 
News Release
For Immediate Release: Feb. 9, 2017
Media Inquiries: Sandy Walsh,
301-796-4669, sandy.walsh@xxxxxxxxxxx  

Consumer Inquiries: 888-INFO-FDA

FDA approves drug to treat Duchenne muscular
dystrophy 
The U.S.
Food and Drug Administration today approved Emflaza (deflazacort) tablets and
oral suspension to treat patients age 5 years and older with Duchenne muscular
dystrophy (DMD), a rare genetic disorder that causes progressive muscle
deterioration and weakness. Emflaza is a corticosteroid that works by
decreasing inflammation and reducing the activity of the immune system. 

Read more. 
###

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Subscriber Services: 
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)